Advancing targeted, controllable, multigenic therapies for cardiovascular diseases
Triple-Gene is a gene therapy company focused on developing advanced therapies for complex cardiovascular diseases.
- 25 million patients globally suffer from heart failure
- ~6.5M patients in the US affected
- About every 90 seconds a person in the US dies from heart disease
Developing a holistic treatment for heart failure requires improvements in angiogenesis, calcium homeostasis-associated cellular energetics, reductions in inflammatory signals, and the activation/recruitment of stem cells to support heart remodeling. We are focused on advancing targeted, controllable, and multigenic gene therapies for the treatment of cardiovascular diseases.
Triple-Gene is a majority-owned subsidiary of Precigen.
Our unique approach implements technologies that are targeted, controllable and multigenic.
- Targeted: We employ genome delivery systems designed to match disease and/or injury-related specifications.
- Controllable: We create modulated gene systems in concert with DNA/RNA/protein-based regulatory motifs, to enable spatiotemporal controls over one or more therapeutic effector molecules.
- Multigenic: We optimize multi-effector therapies to advance treatment or cure underlying disease etiologies and also to ameliorate effects of chronic comorbid tissue damage.
Our Platform Advantages
Triple-Gene’s multigenic therapies are designed to drive expression of three or more potent gene products targeted at reprogramming cells and organs toward a positive health state. Our genetic architecture is built upon a suite of integrated platform technologies. We employ non-viral delivery of DNA to develop therapeutics that address the underlying causes of cardiovascular disease.
- Non-viral delivery eliminates issues of immunogenicity seen with viral-based methods
- Multigenic therapies can target multiple aspects of disease
- Our approach has enabled proof-of-concept to clinical IND in under 24 months.
Administration of our plasmid DNA therapy through the RCSI approach allows for delivery via capillary filtration increased by hydrostatic and osmotic pressures. The efficiency of transduction is dependent on the volume and time of infusion.